Latest News

DAIICHI SANKYO, INC.: ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate, is now available by prescription in the U.S.

AMNEAL PHARMACEUTICALS LLC: Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15, 2020.

SOMOS, INC: New Resp Org IDs to Support the Secondary Market

This month marked a major new step for the Toll-Free industry – the first ever auction to distribute select 833 Toll-Free Numbers (TFNs)!

MIDDLESEX COUNTY REGIONAL CHAMBER OF COMMERCE: First Event of "Make it & Move It Middlesex" Series A Success

The first installment of the chamber’s “Make It and Move It Middlesex” economic development series, which helps to connect local business and legislative leaders, went off without a hitch on Dec. 3.

DAIICHI SANKYO, INC.: DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2 single-arm DESTINY-Breast01 trial of DS-8201 ([fam]-trastuzumab deruxtecan), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 positive metastatic breast cancer.

MIDDLESEX COUNTY REGIONAL CHAMBER OF COMMERCE: Sandler Training Event Helps Members "Identify Blind Spots" Within Their Businesses

Having a company-wide playbook is one of the keys to success in the sales business, according to Dave Mattson, President & CEO of Sandler Training.

NEW JERSEY CHAMBER OF COMMERCE: NJCC Foundation’s Custard joins national workforce development cohort

The president of the state chamber’s foundation will serve as just one of 35 individuals from across the county to participate in a panel focusing on major workforce development and education issues.

ADP, LLC: ADP Anticipates 2020 to Deliver Smart and Personalized Work Experiences for Workers and Employers

Regardless of age, industry or geographic location, as the workforce continues to evolve, so do the needs of workers, businesses and HR leaders.

BRAINSTORM CELL THERAPEUTICS INC.: BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2019, and provide a corporate update, at 8:00 a.m., Eastern Standard Time, on Thursday, November 14, 2019.

DAIICHI SANKYO, INC.: Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology

Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with respect to a collaboration between the two companies from 2008 to 2015 for the development of antibody-drug conjugates (ADCs).

ADP, LLC: ADP Reports First Quarter Fiscal 2020 Results

ADP (Nasdaq: ADP), a leading global technology company providing human capital management (HCM) solutions, today announced its first quarter fiscal 2020 financial results along with its updated fiscal 2020 outlook through an earnings release available on the company's website at

Metro Business Network